Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy

Chitra P 1 , Bakthavatsalam B , Palvannan T

Affiliations 

  • 1 Department of Biochemistry, Penang International Dental College, Vinayaka Mission University, Salem-636308, TamilNadu, India
Clin Chim Acta, 2011 May 12;412(11-12):1151-4.
PMID: 21300045 DOI: 10.1016/j.cca.2011.01.037

Abstract

Acquired immune deficiency syndrome (AIDS) defines the end stage of Human immunodeficiency viral (HIV) infection before the introduction of highly active antiretroviral therapy (HAART). This study was carried out to assess the serum β-2 microglobulin (B2M) as a marker for progression of HIV infected patients undergoing HAART.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications